Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-107A-02 for acute postoperative pain following bunionectomy
NCT06215820Phase 3Completed
- Sponsor
- Viatris
- Start
- Dec 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MR-107A-02 in acute postoperative pain (3 arms), sponsored by Viatris. Primary endpoint: Summed Pain Intensity Difference at 48 hours. Started Dec 2023; status: completed.
02
Drugs
MR-107A-02
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on NCT06215820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215820.